Pharmaceuticals

Kedrab Market Revenue Growth Forecast To Reach $2.04 Billion By 2030 At 5.9% CAGR

May 5, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Kedrab Market During 2026–2030?

The expansion observed in the past can be ascribed to several contributing factors, such as the elevated mortality rates caused by rabies, the widespread dependence on immunoglobulin products, restricted initial access to vaccines, the implementation of public health emergency protocols, and the primary management of rabies within hospital settings.

The expansion in the forecast period is driven by a rise in animal bite incidents, the broadening of rabies awareness initiatives, improvements in emergency care infrastructure, enhanced access to monoclonal antibodies, and increased government funding for rabies prevention. Key developments during this period are expected to include the escalating use of rabies passive immunization, the wider implementation of post-exposure prophylaxis programs, a heightened emphasis on zoonotic disease control, a surge in demand for emergency immunotherapy, and the reinforcement of public health response systems.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20124&type=smp

Which Important Drivers Are Guiding The Kedrab Market Growth?

The growing number of rabies cases is anticipated to stimulate the kedrab market in the future. Rabies, an almost always fatal illness contracted from exposure to rabid animals, presents a serious public health challenge, particularly in areas lacking sufficient access to vaccines. The heightened occurrence of rabies is primarily fueled by inadequate vaccination rates among domestic animals, constrained access to post-exposure prophylaxis, and the widespread presence of rabies in wildlife, especially within underserved regions. Kedrab functions as a human rabies immunoglobulin, delivering immediate passive immunity to individuals exposed to the rabies virus, thus offering crucial protection until vaccination can generate active immunity. For instance, in April 2024, the South Dakota Department of Health, a US-based government agency, indicated that approximately 20 animals in South Dakota were confirmed to have rabies in 2023, representing a 122% increase from the 9 cases reported in 2022. This demonstrates how the increasing incidence of rabies propels the kedrab market.

What Segment Categories Shape The Kedrab Market Segment Landscape?

The kedrab market covered in this report is segmented –

1) By Indication: Post-Exposure Prophylaxis For Rabies, Treatment For Patients Exposed To Suspected Rabid Animals

2) By Formulation: Injectable Formulation, Lyophilized Powder For Reconstitution

3) By Route Of Administration: Intramuscular Injection, Subcutaneous Injection

4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals, Emergency Departments, Specialty Clinics, Public Health Organizations

Which Trends Are Shaping Growth In The Kedrab Market?

Major companies operating in the kedrab market are prioritizing the development of innovative solutions and securing regulatory clearances, such as exclusive licensing and distribution continuation notices, to enhance KEDRAB’s U.S. commercial reach and market presence. An exclusive licensing and distribution continuation notice is a formal announcement from a pharmaceutical or biotechnology company, signifying that an existing agreement granting exclusive rights to license, distribute, or commercialize a specific product has been extended or renewed. For instance, in July 2023, Kamada Ltd., an Israel-based plasma-derived biopharmaceutical company, disclosed that Kedrion Biopharma exercised its option to extend the exclusive U.S. distribution agreement for KEDRAB, a human rabies immune globulin used for post-exposure prophylaxis. KEDRAB offers immediate passive immunity against rabies following potential exposure, boasting established efficacy, safety, and regulatory approval in the U.S. The two-year extension ensures continued availability and supply stability, supporting Kedrion’s commercial distribution infrastructure and strategic presence in the U.S. immunoglobulin market, thereby enhancing patient access and public health preparedness.

Who Are The Companies Operating Across The Kedrab Market Value Chain?

Major companies operating in the kedrab market are Kamada Ltd., Kedrion Biopharma Inc.

Get The Full Kedrab Market Report:

https://www.thebusinessresearchcompany.com/report/kedrab-global-market-report

Which Region Is The Largest In The Kedrab Market?

North America was the largest region in the kedrab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kedrab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Kedrab Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/kedrab-global-market-report

Browse Through More Reports Similar to the Global Kedrab Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Online Fashion Retail Market Report 2026

https://www.thebusinessresearchcompany.com/report/online-fashion-retail-global-market-report

Naphthalene Sulfonate Market Report 2026

https://www.thebusinessresearchcompany.com/report/naphthalene-sulfonate-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795